Hence, all these trials include correlative studies of pharmacokinetics, humoral/cellular responses, and potential biomarkers (including PD-1/PD-L1) in blood and tumor tissue before and after intravesical checkpoint inhibitor instillation in order to fully explore this new approach. Here, CD274 is linked to neoplasm.